AOD-9604 vs Semaglutid

CJC-1295 is a synthetic peptide analogue of GHRH — Growth Hormone Releasing Hormone — the endogenous signal produced by the hypothalamus that travels to the pituitary gland to stimulate GH synthesis and pulsatile release. The natural GHRH molecule (GHRH 1-44) is fragile and rapidly degraded by blood enzymes, giving it a half-life of only 5–7 minutes after injection.

CJC-1295 was engineered to solve this degradation problem. The base structure uses GHRH(1-29) — the biologically active fragment — with four amino acid substitutions at positions 2, 8, 15, and 27 that protect key proteolytic cleavage sites. This gives CJC-1295 significantly improved resistance to serum enzymes compared to native GHRH. The No DAC form achieves approximately a 30-minute half-life; the With DAC form extends this to approximately 8 days through albumin binding.

A critical practical note: in the peptide research market, vendors frequently sell products labeled only as "CJC-1295" without specifying whether DAC is present. Always confirm which form you have. A rough guide: CJC-1295 No DAC (Mod GRF 1-29) has a molecular weight of approximately 3.3 kDa; CJC-1295 With DAC is approximately 3.6 kDa. If injection frequency is unclear from your source's labeling, treat it as No DAC until confirmed.

Short-acting form produces pulsatile GH release — injected 1–3x daily alongside a GHRP for physiologic pulsatility.

Drug Affinity Complex binds serum albumin, extending half-life dramatically. Injected 1–2x per week for continuous GHRH signaling.

CJC-1295 DAC + ipamorelin can raise IGF-1 over 50% from baseline — monitor IGF-1 levels to stay within reference range.